These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 12935976)

  • 1. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas.
    Borchmann P; Morschhauser F; Parry A; Schnell R; Harousseau JL; Gisselbrecht C; Rudolph C; Wilhelm M; Günther H; Pfreundschuh DM; Camboni G; Engert A
    Haematologica; 2003 Aug; 88(8):888-94. PubMed ID: 12935976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Wiernik PH; Lossos IS; Tuscano JM; Justice G; Vose JM; Cole CE; Lam W; McBride K; Wride K; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Habermann TM
    J Clin Oncol; 2008 Oct; 26(30):4952-7. PubMed ID: 18606983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
    Casasnovas RO; Haioun C; Dumontet C; Gabarre J; Richard B; Lederlin P; Caillot D; Stamatoullas A; Morel P; Quesnel B; Blay JY; Bouabdallah K; Gisselbrecht C
    Haematologica; 2000 May; 85(5):502-7. PubMed ID: 10800167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
    Witzig TE; Wiernik PH; Moore T; Reeder C; Cole C; Justice G; Kaplan H; Voralia M; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Vose JM
    J Clin Oncol; 2009 Nov; 27(32):5404-9. PubMed ID: 19805688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
    Aydin S; Dührsen U; Nückel H
    Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
    Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
    Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
    Bremer K
    J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
    Buckstein R; Kerbel RS; Shaked Y; Nayar R; Foden C; Turner R; Lee CR; Taylor D; Zhang L; Man S; Baruchel S; Stempak D; Bertolini F; Crump M
    Clin Cancer Res; 2006 Sep; 12(17):5190-8. PubMed ID: 16951238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma.
    Borchmann P; Schnell R; Knippertz R; Staak JO; Camboni GM; Bernareggi A; Hübel K; Staib P; Schulz A; Diehl V; Engert A
    Ann Oncol; 2001 May; 12(5):661-7. PubMed ID: 11432625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
    Tobinai K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
    Borghaei H; Millenson M; Schilder R; Alden M; Rogatko A; Wang H; Padavic-Shaller K; Smith MR
    Cancer; 2004 Nov; 101(9):2034-41. PubMed ID: 15455357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma.
    Oki Y; McLaughlin P; Pro B; Hagemeister FB; Bleyer A; Loyer E; Younes A
    Cancer; 2005 Aug; 104(4):781-7. PubMed ID: 15973667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).
    Crump M; Baetz T; Couban S; Belch A; Marcellus D; Howson-Jan K; Imrie K; Myers R; Adams G; Ding K; Paul N; Shepherd L; Iglesias J; Meyer R
    Cancer; 2004 Oct; 101(8):1835-42. PubMed ID: 15386331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.
    Faivre S; Raymond E; Boige V; Gatineau M; Buthaut X; Rixe O; Bernareggi A; Camboni G; Armand JP
    Clin Cancer Res; 2001 Jan; 7(1):43-50. PubMed ID: 11205916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxaliplatin/rituximab combination in the treatment of intermediate-low grade non-Hodgkin's lymphoma of elderly patients.
    Addeo R; Caraglia M; Costanzo R; Faiola V; Montella L; Abbruzzese A; Del Prete S
    Oncol Rep; 2004 Jul; 12(1):135-40. PubMed ID: 15201974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study.
    Kahl BS; Bailey HH; Smith EP; Turman N; Smith J; Werndli J; Williams EC; Longo WL; Kim KM; McGovern J; Jumonville A
    Cancer Invest; 2005; 23(1):13-8. PubMed ID: 15779863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease.
    Younes A; Pro B; Robertson MJ; Flinn IW; Romaguera JE; Hagemeister F; Dang NH; Fiumara P; Loyer EM; Cabanillas FF; McLaughlin PW; Rodriguez MA; Samaniego F
    Clin Cancer Res; 2004 Aug; 10(16):5432-8. PubMed ID: 15328181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.
    Leonard JP; Coleman M; Ketas JC; Chadburn A; Furman R; Schuster MW; Feldman EJ; Ashe M; Schuster SJ; Wegener WA; Hansen HJ; Ziccardi H; Eschenberg M; Gayko U; Fields SZ; Cesano A; Goldenberg DM
    Clin Cancer Res; 2004 Aug; 10(16):5327-34. PubMed ID: 15328168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.
    Friedberg JW; Cohen P; Chen L; Robinson KS; Forero-Torres A; La Casce AS; Fayad LE; Bessudo A; Camacho ES; Williams ME; van der Jagt RH; Oliver JW; Cheson BD
    J Clin Oncol; 2008 Jan; 26(2):204-10. PubMed ID: 18182663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.